Bayer Sees Pharma Growth as Unit Chief Touts Comeback Story (1)

Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales lost to patent expirations.

“Bayer is truly turning a corner,” Stefan Oelrich,who heads the German company’s pharma business, said in an interview at the JPMorgan Healthcare Conference in San Francisco. “This is a real comeback story.”

The ailing conglomerate is heading into a crucial year as Chief Executive Officer Bill Anderson works to contain the drugs-to-herbicides company’s biggest overhang — a wave of litigation tied to its Roundup weed killer — by the end of 2026. ...